Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A 600276
SSE · China · Health Technology
CNY 47.20+1.58 (+3.46%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
U.S. District Judge Richard G. Andrews of the District of Delaware found on Wednesday that Liquidia induces infringement of claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327.
Major shareholder announcement Reference is made to the press release issued by Coloplast A/S on 4 September 2026 regarding the expected implementation of the generational change in the ultimate ownership of Coloplast A/S. Coloplast A/S hereby announces that on 1 October 2026, Coloplast A/S has received the following major shareholder notification: NPLH Holding ApS, a company 100% owned and controlled by Niels Peter Louis-Hansen, has transferred, by way of a gift, all its shares in Coloplast Hol
TempraMed Technologies (VIVI.CN) closed its non-brokered private placement offering of unsecured con
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.